Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?
Amgen (AMGN) reported positive Phase 3 trial data for its Sjögren's disease drug, dazodalibep, boosting its autoimmune pipeline. The stock has surged 17.2% in 90 days and 29.3% year-to-date. Analysts debate its valuation, with one model suggesting it's overvalued at $423.64 vs. a fair value of $359.98, while another DCF model estimates it's undervalued at $672.77.
How this was made
The 30-second read
Why it matters
Positive trial data is a fresh catalyst that could shift market perception and trigger buying pressure.
Market read
Amgen's trial news is the primary market‑moving event; peers are mentioned only for comparison.
What to watch
Potential regulatory delays and competition in obesity space may dampen long‑term gains.
Background
The article provides a valuation debate around Amgen after its Phase 3 trial news, contrasting overvalued vs undervalued narratives.
Ticker impact
Amgen reported positive topline Phase 3 data for its OASIZ 301 trial of dazodalibep in Sjögren's disease, a new clinical result not previously disclosed.
likely upward pressure as market prices in the favorable trial outcome
Phase 3 success is a material catalyst for a biotech; the article is the first report of the data, suggesting fresh buying interest.
Market effects
May boost sentiment for autoimmune and biotech sector peers.
US biotech market could see modest gains.
Limited to biotech investors; no broad macro impact.
Counterpoint
Valuation remains high; legacy franchise erosion could limit upside.
Key entities
- companyAmgen
US‑listed biotech firm (ticker AMGN) reporting Phase 3 trial results.
